TTX MC 138
Alternative Names: TTX-MC-138Latest Information Update: 06 May 2026
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Colorectal cancer; Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified
Most Recent Events
- 27 Apr 2026 TransCode Therapeutics enters into a sponsored research agreement (SRA) with Michigan State University to develop TTX M 138 in combination with seviprotimut-L
- 05 Feb 2026 TransCode Therapeutics files an IND application to the US FDA for Colorectal cancer
- 06 Jan 2026 TTX MC 138 is still in Preclinical trials for Glioblastoma in the US